0001683168-19-003238.txt : 20191011 0001683168-19-003238.hdr.sgml : 20191011 20191011161013 ACCESSION NUMBER: 0001683168-19-003238 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 20191007 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20191011 DATE AS OF CHANGE: 20191011 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Cannabics Pharmaceuticals Inc. CENTRAL INDEX KEY: 0001343009 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203373669 STATE OF INCORPORATION: NV FISCAL YEAR END: 0831 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-52403 FILM NUMBER: 191148262 BUSINESS ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: 877-424-2429 MAIL ADDRESS: STREET 1: #3 BETHESDA METRO CENTER STREET 2: SUITE 700 CITY: BETHESDA STATE: MD ZIP: 20814 FORMER COMPANY: FORMER CONFORMED NAME: American Mining Corp DATE OF NAME CHANGE: 20110510 FORMER COMPANY: FORMER CONFORMED NAME: Thrust Energy Corp. DATE OF NAME CHANGE: 20051031 8-K 1 cannabics_8k.htm FORM 8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): October 7, 2019

 

CANNABICS PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

 

 

Nevada 000-52403 20-3373669
(State of incorporation) (Commission File Number) (IRS Employer No.)

 

 

#3 Bethesda Metro Center

Suite 700

Bethesda, Md 20814

(Address of principal executive offices and Zip Code)

 

877 424-2429

(Registrant's telephone number, including area code)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on
which registered
Common Stock, par value $0.0001 per share   CNBX   OTCQB

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company   ☐         

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

   

 

 

 

ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.

 

On October 7th, 2019, Ehud Reiger and Eyal Ballan resigned from their positions as Directors and Board Members of the Company. Eyal Ballan remains as the Chief Technical Officer of the Company.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

The following Exhibits are filed as part of this Current Report.

  

 

Exhibit  
Number Description
   
10.1 Letter of Resignation of Ehud Reiger
10.2 Letter of Resignation of Eyal Ballan

 

 

 2 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

 

Dated: October 11, 2019 CANNABICS PHARMACEUTICALS, INC.
     
  By: /s/ Eyal Barad
  Name:  Eyal Barad
  Title: Chief Executive Officer

 

 

 

 

 

 

 

 

 

 

 3 

 

 EX-10.1 2 cannabics_ex1001.htm RESIGNATION OF EHUD REIGER

Exhibit 10.1

 

Resignation of Ehud Reiger

as Director

of

CANNABICS PHARMACEUTICALS INC.

 

The following is a true copy of the Resignation as Director and Board Member of the Corporation, as of this 7th day of October, 2019;

 

WHEREAS the undersigned was appointed as Director and Board Member of the Corporation and has served in said capacity to date, he has determined at this time to formally RESIGN and renounce all further corporate designation or affiliation with the Company, and severs any and all officials ties, duties, obligations or liabilities regarding Cannabics Pharmaceuticals Inc., and does hereby, by affixing, his signature hereto, officially as his last corporate act, DOES HEREBY RESIGN.

 

 

 

 

DATED: 7th October, 2019

 

 

 

/s/ Ehud Reiger                             

Ehud Reiger

 

 EX-10.2 3 cannabics_ex1002.htm RESIGNATION OF EYAL BALLAN

Exhibit 10.2

 

Resignation of Eyal Ballan

as Director

of

CANNABICS PHARMACEUTICALS INC.

 

The following is a true copy of the Resignation as Director and Board Member of the Corporation, as of this 7th day of October, 2019;

 

WHEREAS the undersigned was appointed as Director and Board Member of the Corporation and has served in said capacity to date, he has determined at this time to formally RESIGN and renounce all severs any and all officials ties, duties, obligations or liabilities regarding his position as Director and Board Member of Cannabics Pharmaceuticals Inc. Though he remains as the Company’s Chief Technical Officer, does hereby, by affixing, his signature hereto, DOES HEREBY RESIGN from said Board and Director positions.

 

 

 

 

DATED: 7th October, 2019

 

 

 

/s/ Eyal Ballan                                     

Eyal Ballan